McKesson CEO Tyler Brian S. sells shares for $13.67 million

McKesson CEO Tyler Brian S. sold 19,370 shares of MCK on June 6, 2025, for approximately $13.67 million under a pre-established trading plan. The sale follows McKesson's recent fiscal fourth-quarter earnings, which beat EPS expectations at $10.12 but missed revenue targets at $90.82 billion, and the completion of a $2.49 billion acquisition of a 70% stake in Core Ventures; Jefferies has raised its price target to $800 with a Buy rating, citing the company's strong financial performance and guidance.

Analysis

McKesson Corp (NYSE:MCK) CEO Tyler Brian S. executed a sale of 19,370 shares on June 6, 2025, at $705.93 per share, totaling approximately $13.67 million. This transaction was conducted under a pre-established Rule 10b5-1(c) trading plan adopted on November 8, 2024, which allows insiders to set up predetermined selling schedules, and notably, the CEO retains direct ownership of 51,243 shares. This insider activity occurs as McKesson's stock is trading near its 52-week high of $731, reflecting a significant 22% gain over the past year and a consistent dividend payment history spanning 32 consecutive years. The company recently reported mixed fiscal fourth-quarter results: adjusted earnings per share (EPS) of $10.12 surpassed the $9.81 forecast, indicating strong profitability. However, revenue of $90.82 billion fell short of the projected $93.48 billion. Despite this revenue miss, McKesson's management maintains an optimistic long-term EPS growth outlook of 12%-14%. Supporting this outlook are key strategic initiatives, including the completed acquisition of a 70% controlling interest in Core Ventures for approximately $2.49 billion, a move aimed at enhancing community-based oncology care and expected to contribute significantly to growth in the U.S. Pharmaceutical segment. Furthermore, McKesson announced plans to separate its Medical Surgical segment into an independent entity to enhance operational efficiency. Reinforcing a positive market view, Jefferies analyst Rob Dickerson raised McKesson's stock target to $800 and maintained a Buy rating, citing the company's robust financial performance and favorable forward guidance.

Key Decisions for Investors

• Investors should consider the CEO's stock sale as mitigated by its pre-planned nature under a Rule 10b5-1(c) plan and his remaining significant shareholdings, rather than an immediate negative signal on the company's prospects.
• The mixed Q4 results, with an EPS beat but a revenue shortfall, warrant careful consideration; however, the maintained long-term EPS growth guidance of 12%-14% and strategic moves like the Core Ventures acquisition and Medical Surgical segment separation suggest potential for continued growth.
• Given the stock is trading near its 52-week high and has a new $800 price target from Jefferies, investors should assess the current valuation in light of future growth prospects and the successful execution of announced strategic realignments.
• Monitor the integration of Core Ventures and the progress of the Medical Surgical segment separation, as the successful execution of these initiatives will be key to achieving projected growth and operational efficiencies.